Celldex to Present at the 2022 Jefferies Global Healthcare Conference
06/06/2022 - 04:05 PM
HAMPTON, N.J., June 06, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that senior management will participate in a fireside chat at the 2022 Jefferies Global Healthcare Conference in New York City on Wednesday, June 8, 2022 at 8:30 a.m. ET.
A webcast of the presentation will be available on the "Events & Presentations" page of the "Investors & Media " section of the Celldex website. A replay will be available for 30 days following the event.
About Celldex Therapeutics, Inc. Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer. Visit www.celldex.com .
Company Contact Sarah Cavanaugh Senior Vice President, Corporate Affairs & Administration (508) 864-8337scavanaugh@celldex.com
Patrick Till Senior Director, Investor Relations & Corporate Communications (484) 788-8560ptill@celldex.com
Celldex Therapeutics Inc.
CLDX Rankings
#4135 Ranked by Stock Gains
CLDX Stock Data
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Medical Specialties, Manufacturing, Biological Product (except Diagnostic) Manufacturing
Country
US
City
Hampton
About CLDX
celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. celldex therapeutics (nasdaq: cldx) was founded based on a fundamental scientific belief that harnessing the power of the immune system would break significant barriers in drug development for a host of devastating diseases. the company's pipeline is comprised of therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines that we believe have a higher probability of success because they are targeted to specific patient populations with high unmet medical need whose diseases express specific markers, including many underserved or completely un-served orphan indications. this has created a leading pipeline in im